|Trade names||Anturan, Anturane, Apo-sulfinpyrazone|
|By mouth intravenous|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||404.48 g·mol−1|
|3D model (JSmol)|
Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.
Trial have found that, Sulfinpyrazone taken in specific daily dose immediately following a patient having suffered from a myocardial infraction seem to drastically reduce the incidence of sudden death by as much as 43% and cardiac mortality by 32% in the 24 months following their heart attack. 
- Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.
- "Sulfinpyrazone in the Prevention of Sudden Death after Myocardial Infarction". New England Journal of Medicine. 302 (5): 250–256. 1980-01-31. doi:10.1056/NEJM198001313020502. ISSN 0028-4793. PMID 6985706.